ReviewCurrent opinion in nephrology and hypertension2020
Pharmacologic and psychological interventions for depression treatment in patients with kidney disease.
Review in Current opinion in nephrology and hypertension, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 72 citations in OpenAlex.
- Effects of health education based on self-determination theory on hemodialysis knowledge and self-management in maintenance hemodialysis patients.Scientific reports · 2025Trial
- Far-infrared stimulation of Neiguan acupoints improves heart rate variability and ameliorate fatigue in hemodialysis patients: A randomized trial.Journal of the Chinese Medical Association : JCMA · 2024Trial
- Design and Baseline Characteristics of CONCORD, a Trial of Novel Therapies for Depression in CKD.Kidney international reports · 2026Article
- Mental Health Disorders in End-Stage Kidney Disease: A Narrative Review of Clinical Considerations for Integrated Management.Hemodialysis international. International Symposium on Home Hemodialysis · 2026Review
- Mental health and kidney disease.Nature reviews. Nephrology · 2026Review
- Quality of life, sleep quality, and psychological wellbeing of patients with chronic kidney disease in Sabaragamuwa Province, Sri Lanka: a descriptive cross-sectional study.Scientific reports · 2026Article
- Assessment of Depression and Anxiety in Hemodialysis Patients Undergoing VR Therapy-Pilot Study.Journal of clinical medicine · 2026Article
- A critical appraisal of integrating family constellation therapy with pharmacological treatment for depression.Frontiers in psychiatry · 2026Review
- Development and usability evaluation of an audio-based cognitive behavioral therapy mobile app for depression in hemodialysis patients.BMC psychology · 2025Article
- Interaction between anxiety, depression, and low resilience predicts poor prognosis in patients with chronic kidney disease.World journal of psychiatry · 2025Article
- Severe Mental Illness in CKD: Why it Matters.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2025Article
- Bupropion decreases plasma levels of asymmetric dimethylarginine and ameliorates renal injury by modulation of Ddah1, Oatp4c1, Oct2, and Mate1 in rats with adenine-induced chronic renal injury.Frontiers in pharmacology · 2025Article
- Safety and efficacy of sertraline in depression among adults undergoing dialysis: a systematic review and meta-analysis.Annals of medicine and surgery (2012) · 2024Article
- Sleep quality and associated factors among patients with chronic kidney disease in Nigeria: a cross-sectional study.BMJ open · 2023Article
- Drugs with a negative impact on cognitive functions (Part 2): drug classes to consider while prescribing in CKD patients.Clinical kidney journal · 2023Review
- High rates of psychological distress, mental health diagnoses and suicide attempts in people with chronic kidney disease in Ireland.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2023Article
- [Long-term physical and psychological consequences of chronic kidney disease].Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz · 2022Review
- Frailty as an Independent Risk Factor for Depression in Patients With End-Stage Renal Disease: A Cross-Sectional Study.Frontiers in medicine · 2022Article
- How Are Albertans "Adjusting to and Coping With" Dialysis? A Cross-Sectional Survey.Canadian journal of kidney health and disease · 2022Article
- "Together We Stand": A Pilot Study Exploring the Feasibility, Acceptability, and Preliminary Effects of a Family-Based Psychoeducational Intervention for Patients on Hemodialysis and Their Family Caregivers.Healthcare (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
purpose of reviewIt remains controversial whether existing therapies, including pharmacologic and psychological interventions, are effective for treatment of depression in patients with chronic kidney disease (CKD) and end-stage kidney disease. RECENT
findingsMost studies of depression treatment were underpowered or uncontrolled. The CKD Antidepressant Sertraline Trial showed no benefit of a serotonin-selective reuptake inhibitor (SSRI), sertraline, over double-blind matched placebo for the treatment of depressive symptoms in patients with nondialysis CKD. A Trial of Sertraline vs. Cognitive Behavioral Therapy (CBT) for End-stage Renal Disease Patients with Depression showed improvement in depressive symptoms from baseline in both groups and a marginal benefit of sertraline over CBT that was of unclear clinical significance, given the lack of an active control group. SSRIs are associated with poor tolerability in clinical trials and serious adverse outcomes in large retrospective studies. SUMMARY: Although the data do not support unlimited use of SSRIs in patients with CKD or end-stage kidney disease, it is reasonable to initiate a cautious trial of sertraline while closely monitoring for depressive symptom improvement and adverse effects. CBT is a low-risk, possibly effective intervention to treat major depressive disorder in patients with kidney disease who have access to such treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.